Astellas ends work on anti-osteopontin antibody for rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
Astellas has terminated a development programme for its lead anti-human osteopontin antibody, ASK8007, for rheumatoid arthritis, following disappointing results from a Phase I trial.